FREQUENTLY ASKED QUESTIONS

As the sunsetting process for Clinical Research Financial Clearance proceeds toward the June 1st, 2023 end date questions and answers related to the processes to provide clarity will be shared regularly.

FAQs (Series 1)

Q: Will the Financial Responsibility Sheet be discontinued? Do I still need to provide it at the time of consent?

A: The Financial Responsibility Sheet developed by CRSS is still mandatory for any study with a Prospective Reimbursement Analysis status of PRA=YES. Even after June 1st, 2023, the Financial Responsibility Sheet must be provided to the patient during consent to provide an overview of the cost breakdown between study-paid and patient-responsibility services associated with the protocol. This sheet helps outline for patients the financial implications of participating in the study, including the costs typically covered by insurance.

Q: I’m concerned that we’re no longer using CRMS, and we don’t have anyone to ensure that our patients are not billed for study-related care.

A: The clinical research financial clearance submission (CRFC) process in CRMS operate separately from the bill hold processes in Epic. The consent form and Financial Responsibility Sheet clearly outline what is the patient’s responsibility (typically covered by insurance) and what is sponsor-paid for the protocol. Only instances where the Financial Responsibility Sheet indicates all protocol-related events are covered by the study can we assure that there will be no billing to the patient for study-related care.

Q: Will the Epic research billing hold be discontinued as well?

A: There are no changes to the research billing hold process. Both CRMS and OnCore interface with Epic to enable the billing hold and review for clinical trial participants.

Q: Will the CRBC group still review charges before anything is sent to insurance for patient billing?

A: Yes, the Clinical Research Billing Compliance (CRBC) team will continue to review all billing for patients in an active status (Candidate, Consented, Eligible, Enrolled, Follow-Up) in CRMS. In the future the same hold and review process will be built into OnCore, ensuring charges in Epic are accurately sent to patient coverage or billed to the study RSH account.

QUESTIONS?

Contact Scott Streibich, Director – Clinical Research Revenue Cycle, JHU SOM Office of Clinical Trials at streib1@jhu.edu or reach out to Clinical Research Support Services at CRSS@jhmi.edu

Sign up for the project newsletter and review related OnCore CTMS information here.

Clinical research billing information and helpful contacts are available at this weblink: JHM Research Revenue Cycle Website

2023 Update: Clinical Research Financial Clearance